Table 1 Patients’ characteristics
From: Neurobiological substrates of chronic low back pain (CLBP): a brain [99mTc]Tc-ECD SPECT study
Patient | Age(y) | Gender | LDH | Durationof pain | Medications in use |
|---|---|---|---|---|---|
1 EMVB | 38 | F | L4–L5, Early fractured L2 | 1 y | Amitriptyline, sertraline, clonazepam |
2 VC | 44 | M | L4–L5 | 2 y | – |
3 LDC | 31 | M | L4–L5–S1 | 3 y | Acetaminophen |
4 JAT | 62 | M | L4–L5 | 10 y | Cytidine, uridine, hydroxocobalamin |
5 EAS | 48 | M | L2–L3–L4 | 6 y | – |
6 ACAVS | 33 | F | L4–L5–S1 | 3 m | – |
7 PHM | 41 | M | L4–L5 | 4 y | Anthraquinone, prednisone, thiamine |
8 TCCM | 35 | F | L5–TV | 1 y 8 m | – |
9 IRR | 48 | F | L3–L4 | 3 y | Paroxetine, bupropion, clonazepam |
10 IR | 50 | M | L4–L5 | 1y 6 m | Dexamethasone, betamethasone dipropionate, ketoprofen, celecoxibe, cyclobenzaprine |
11 KDBBS | 25 | F | L4–L5 | 1 y | – |
12 MECO | 34 | F | L4–L5 | 1 y 6 m | Nimesulide, dipyrone |
13 CHFCF | 37 | F | L4–L5 | 12 y | – |
14 JBC | 41 | F | L4–L5–TV | 10 y | – |